ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain. The US market for Etodolac 300mg capsules totals $9 million on a trailing 12 month basis, per IMS Health. Prior to today's announcement, only two companies marketed the product.
Arthur S. Przybyl, President and Chief Executive Officer said, "We are pleased to announce the launch of our second product from the portfolio of approved generic products we acquired from Teva in January 2014."
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients